Eficacy and safety of the combination of trastuzumab, liposome-encapsulated doxorubicin and paclitaxel as neoadjuvant scheme in HER-2 positive breast cancer patients.
Phase of Trial: Phase IV
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Doxorubicin (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2017 New trial record